Major histocompatibility complex class II presenting Dermatophagoides pteronyssinus allergen 2 peptides (MHC II-Der p 2)

MHC class II molecules presenting Der p 2 peptides are critical immunological complexes formed when antigen-presenting cells process the major house dust mite allergen, Dermatophagoides pteronyssinus allergen 2 (Der p 2), and display its epitopes to CD4+ T cells. This interaction is a cornerstone of the allergic immune response, leading to the activation of Th2 cells, production of IgE, and subsequent inflammatory symptoms in conditions like allergic asthma and rhinitis (Source: PMID: 25617480). As a therapeutic target, these complexes are utilized in peptide-based immunotherapy (PIT), where specific synthetic peptides are designed to bind MHC II molecules without cross-linking IgE on mast cells (Source: PMID: 28434687). This approach aims to induce peripheral T-cell tolerance or shift the immune response toward a regulatory phenotype, effectively desensitizing the patient to the allergen (Source: PMID: 17456219). Research into TCR-like antibodies and pMHC-specific therapies continues to explore these complexes as precise tools for modulating allergen-specific immunity. Monitoring these complexes using pMHC tetramers allows for the tracking of allergen-specific T-cell populations during clinical trials (Source: PMID: 22403251).

Other names

MHC class II-Der p 2 complexHLA-DR-Der p 2House dust mite allergen Der p 2-MHC II complexpMHC II (Der p 2)

Peptide-based immunotherapy (PIT) involves the administration of allergen-derived peptides that bind to MHC class II molecules to induce T-cell anergy, deletion, or the induction of regulatory T cells (Tregs), thereby suppressing Th2-mediated allergic inflammation.